SCHEMBL23069180

SCHEMBL23069180

COc1ccc(Cn2nc(Cl)c3cc(Oc4ccc([N+](=O)[O-])cc4)cnc32)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ SLC29A1 Q99808 1/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ CNR2 P34972 3/20 0.42
▸ ACHE P22303 2/20 0.42
▸ NPBWR1 P48145 2/20 0.42
▸ KCNJ1 P48048 1/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ CNR1 P21554 1/20 0.42
▸ PIK3R1 P27986 1/20 0.41
▸ PIK3CA P42336 1/20 0.41
▸ PDE5A O76074 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29872970 0.89 MAPT (0.49) MAPTSMN1; SMN2SLC29A1KMT2ANPC1
SCHEMBL29873129 0.85 MAPT (0.46) MAPTSMN1; SMN2SLC29A1KMT2ANPC1
SCHEMBL29872929 0.84 NPBWR1 (0.43) MAPTSMN1; SMN2CNR2NPBWR1CNR1
SCHEMBL1593005 0.77 MAPT (0.51) MAPTSMN1; SMN2SLC29A1KMT2ANPC1
SCHEMBL28975938 0.75 MAPT (0.48) MAPTSMN1; SMN2SLC29A1KMT2ANPC1
SCHEMBL29873266 0.74 MAPT (0.45) MAPTSMN1; SMN2SLC29A1KMT2ANPC1
SCHEMBL1593522 0.74 CNR2 (0.50) MAPTSMN1; SMN2SLC29A1KMT2ANPC1
SCHEMBL29873567 0.72 MAPT (0.44) MAPTSMN1; SMN2SLC29A1KMT2ANPC1
SCHEMBL3112343 0.72 MAPT (0.50) MAPTSMN1; SMN2SLC29A1KMT2ANPC1
SCHEMBL28975914 0.71 MAPT (0.49) MAPTSMN1; SMN2SLC29A1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220306640-A1 HYDANTOIN DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2022-09-29 — — US disclosed
EP-4025570-A1 HYDANTOIN DERIVATIVE ONO Pharmaceutical Co., Ltd. (JP) 2022-07-13 — — EP disclosed
WO-2021043245-A1 HYDANTOIN DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2021-03-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220306640-A1 HYDANTOIN DERIVATIVE DDR1, DDR2, DDRGK1 MAPT 3943/4885SMN1; SMN2 1226/4885SLC29A1 828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback